Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Makes Rare Call, Removes Boxed Warning From Chantix, Zyban Labels

Executive Summary

Pfizer, GSK score as neuropsychiatric symptom risks now only appear in Warnings and Precautions section following EAGLES trial results.

You may also be interested in...

Chantix's Boxed Warning: Will A Positive Vote Justify A Negative Outcome?

FDA could use advisory committee members' comments to maintain the smoking cessation drug's boxed warning, even though they voted to remove it.

Pfizer's Pitch For Chantix Warning Reduction Focuses On Those With Mental Illness

Those patients need more options for smoking cessation, Pfizer says, but that is the group FDA most worries about when deciding whether to remove its boxed warning.

Was FDA Nit-Picking In Criticism Of Pfizer's EAGLES Trial?

When industry rep questioned whether problems with smoking cession drug trial were overestimated, FDA's rebuke was swift.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts